Interferon (IFN) ",/, a cardinal proinflammatory cytokine, induces expression of the gene products of the class II locus of the major histocompatibility complex (MHC), whereas IFN-0t or -[3 suppresses MHC class II expression. The mechanism of IFN-13-mediated MHC class II inhibition has been unclear. Recently, a novel factor termed class II transactivator (CIITA) has been identified as essential for IFN-~/-induced MHC class II transcription. We studied the status of IFN-~/-induced CIITA messenger P, NA (mI(NA) accumulation and CIITA-driven transactivation in IFN-13-treated cells and used cell lines that had defined defects in the type I IFN response pathway to address the roles of IFN signaling components in the inhibition of MHC class II induction. IFN-~ treatment did not suppress IFN-~-induced accumulation of CIITA mR~A. After cells were stably transfected with CIITA, endogenous MHC class II genes were constitutively expressed, and MHC class II promoters, delivered by transfection, were actively transcribed in CIITA-expressing cells. Expression of these promoters was significantly impaired by pretreatment with IFN-[3. These results suggest that IFN-[3 acts downstream of CIITA mRNA accumulation, and acts in part by reducing the functional competence of CIITA for transactivating MHC class II promoters. IFN stimulated gene factor 3 (ISGF3) was essential for IFN-[3 to mediate inhibition of MHC class II induction, regardless of whether MHC class II transcription was stimulated by IFN-~ or directly by CIITA expression. Results of these experiments suggest that inhibition of MHC class II in IFN-[3-treated cells requires expression of gene(s) directed by the ISGF3-IFN-stimulated response element pathway, and that these gene product(s) may act by blocking CIITA-driven transcription of MHC class II promoters.
B
iochemical and genetic studies of signaling by the IFNs recently culminated in a convincing and lucid description of the process by which type I IFNs induce transcription of a set of immediate response genes, termed the IFNresponsive genes (ISGs) 1 (1) . This pathway has been proposed 1Abbreviations used in this paper: CAT, chloramphenicol acetyltransferase; CIITA, class II transactivator; EMSA, electrophoresis mobility shift assay; GAS, T-activated sequence; ISG, IFN-responsive gene; ISGF3, IFNstimulated gene factor 3; ISRE, IFN-stimulated response element; mRNA, messenger RNA; MS, multiple sclerosis; PTK, protein tyrosine kinase; STAT, signal transducer and activator of transcription.
as a paradigm for a "direct effector" model of transcriptional regulation by cytokines, involving protein-protein interactions to form a transcriptional activator, IFN-stimulated gene factor 3 (ISGF3), which can activate transcription via an inducible enhancer, the IFN-stimulated response element (ISRE). Upon receptor binding by IFN-ot or IFN-~, latent cytoplasmic transcription factors, collectively termed ISGF3-ot, were shown to be phosphorylated on tyrosine residues and to accumulate in the nucleus, where they formed a complex with a 48-kD DNA-binding protein, designated ISGF3-~/. These components were designated ISGF3, which was shown to be essential to induce transcription from ISG promoter/enhancer elements containing ISILEs.
Unexpectedly, this research revealed that type I (IFN-a or IFN- [3) and type II (IFN-3') IFNs, despite signaling through unique receptors, share certain transcriptional regulatory components (2) . In particular, a 91-kD ISGF3-0~ component, designated signal transducer and activator of transcription (STAT) 10~, and a nonreceptor protein tyrosine kinase (PTK) termed JAK1, proved to be absolutely required for response to both types I and II IFNs (2) (3) (4) . Other components, such as the transcription factors ISGF3-',/ and p113/STAT-2, as well as the PTK tyk2, were implicated particularly in signaling by the type I IFNs. The PTK JAK2 was used specifically by IFN-~/ (1, 5, 6) . These results explained previously described signaling interactions between the partially overlapping pathways used by the two IFN types (7) .
The ISGs encode products that mediate the biological consequences of IFN treatment, including antiviral, growthregulatory, and immune-modulatory effects (8) . Prominent among these effects, IFN treatment regulates expression of MHC antigens (8) . Either of the two IFN subtypes, type I or type II IFN, up-regulate expression of MHC class I antigens (9) . It has been shown that MHC class II antigens were responsive to IFN-% whereas IFN-ot and -13 were typically unable to induce MHC class II expression (9) . In fact, for many cell types, type I IFN was shown to block the induction of MHC class II expression by IFN-~/(10-12). These contrasting consequences oflFN-~/and IFN-[3 treatment for MHC class II expression might be ofpathogenetic significance, as IFN-~/and IFN-[~ recently exhibited highly divergent effects in regulating the human inflammatory demyehnating disorder multiple sclerosis (MS). MS patients treated with IFN-~/experienced elevated disease activity, accompanied by immune stimulation (13, 14) . Patients treated with IFN-~ experienced fewer and milder attacks, with diminished disease progression as monitored by magnetic-resonance brain scanning (15, 16) . IFN-[3 may ameliorate MS by down-regulating pathogenic MHC class II expression in the affected central nervous system tissues (17) .
In this regard, we and others have shown that IFN-[3-mediated blockade of IFN-~/-induced MHC class II expression occurred at the transcriptional level (18, 19) . Transcriptional suppression of MHC class II by IFN-[3 was relatively gene specific and did not require sequence content, beyond the conserved MHC class II cis-regulatory elements that were also required for response to IFN-',/ (20) .
MHC class II expression has been intensely investigated in recent years (9, (21) (22) (23) (24) . Expression of MHC class II was shown to be regulated developmentally and environmentally, in a remarkably specific and stringent fashion. Transcriptional activity of the MHC class II genes has been shown to determine their expression, and several lines of evidence have indicated selective transcriptional control of the MHC class II genes. The strongest support for this notion came from human patients with bare lymphocyte syndrome, an autosomal-recessive deficiency of MHC class II gene expression (25) . Further, two groups generated cell 1518 lines with selective defects in the IFN-y pathway for MHC class II expression (26, 27) . MHC class II gene induction by IFN-y required intermediary protein synthesis in most cells (28, 29) . Additionally, the regulatory cis element for MHC class II transcription was quite different from the y-activated sequence (GAS) element that governed the direct (protein synthesis-independent) response to IFN-~/ (1). Taken together, studies of IFN-~/induction of MHC class II transcription indicated an indirect mechanism requiring synthesis of a protein factor, in addition to the direct JAK-STAT pathway. Class II transactivator (CIITA), a novel transcription factor deficient in one bare lymphocyte syndrome complementation group, has recently been identified by a variety of genetic and biochemical strategies as the IFN-y-inducible factor that was necessary for MHC class II transcription (30) (31) (32) (33) .
Based on recent reports, ClITA is proposed to activate MHC class II transcription by interacting (directly or indirectly) with factors bound to regulatory DNA elements upstream of the structural genes (34, 35) . Furthermore, CIITA contains a potent NH2-terminal transactivation domain that functions in heterologous context (34, 35) . Taken in aggregate, these observations prompted the attractive hypothesis that physical interaction between CIITA and promoterbound components positions the transactivator domain to provide a stimulatory interface between the MHC class II gene-specific factors and the basal transcription apparatus (34, 35) .
Experiments described in this report addressed the role of CIITA in the pathway by which IFN-[3 inhibited MHC class II expression. Additionally, cell lines with defined defects in type I IFN signaling were used to address the functions of individual ISR.E-ISGF3 signaling components. Initial experiments were performed in the parental fibrosarcoma cell line 2fTGH, which responds to IFN-~ with expression of MHC class II antigens, and this induction can be readily suppressed by IFN-[3. As anticipated, CIITA messenger RNA (mRNA) accumulated in 2fTGH cells after induction with IFN-~/. We found that IFN-13 treatment did not suppress IFN-~-induced CIITA mRNA accumulation. 2fTGH cells that were stably transfected with a CIITA expression construct displayed MHC class II antigens in the absence oflFN-% and MHC class II promoter/ reporters were strongly activated in CIITA-transfected ceils. IFN- [3 pretreatment Plasmids. Construction ofpCIITA.2.11 and its use to direct expression of functional CIITA have been described (31, 35) . Construction of pDRA(267)CAT was previously described (20) . Cell Culture. 2fTGH and all derivative cell lines were grown in complete medium: DME with 10% heat-inactivated FCS (GIBCO/BRL, Gaithersburg, MD) and 250 Ixg/ml ofhygromycin B (Sigma Chemical Co., St. Louis, MO) (36) .
Mutant Cell Lines Defective in Response to IFN-ec/fl. The 2fTGH
fibrosarcoma cell line and derivative mutants exhibiting defects in their response to IFN-cx were generated by lethal selection (37) . Recessive mutant cell lines were organized into complementation groups, designated U (unresponsive)-1 through U-6 (1, 37). Each complementation group contains one or more cell lines that are genetically defective for individual components of the IFN signaling pathway (1, 2, 36-38). The parental cell line 2fTGH exhibits wild-type response to types I and II IFN (36) . U1A (initially designated 11.1) lacks tyk2 and is unresponsive to IFN-ot, but retains partial response to IFN-13 and full response to IFN-~/ (6, 36) . U2A lacks functional ISGF3-~ and is unresponsive to IFN-ci and IFN-13 for gene expression directed by the ISRE, but retains full response to IFN-oe for an ISILE/ISGF3-independent pathway (1, 6, 36, 38, 39) . U2A cells activate all IFN-~/-responsive genes tested (including the MHC class I and II antigens) except 1-8 and 9-27 (1, 38--40).
Cell Lines Expressing CIITA 2.11. For these studies, 2fTGH
and derivative cell lines were cultured in 10-cm 2 dishes to "~70-80% confluence and incubated with prewarmed complete medium containing pCIITA.2.11 and pSV2neo (41) plasmid DNAs (in 10:1 molar ratio) and 10 Ixg/rnl hexadimethrine bromide (Polybrene; Sigma Chemical Co.) for 6 h. Cells were washed once with PBS and shocked for 2 rain with 30% DMSO (Sigma Chemical Co.). The cells were incubated in 10 ml complete medium for 2 d and subjected to selection in complete medium supplemented with 500 ~g/ml G418 (Sigma Chemical Co.) for 2-3 wk.
Restoration of lSGF3-y Activity in U2A Cells. U2A cells were transfected with pDRISGF3"? (kindly provided by Dr. Ganes Sen, Research Institute, Cleveland Clinic Foundation) and pSV2neo DNA in 10:1 molar ratio, subjected to selection for G418 (500 ~g/ml) resistance for 2 wk, and then selected for restoration of type I IFN response in DME containing IFN-oe (Wellferon, 500 U/ml) and 1• hypoxanthine-aminopterin-thymidine medium (GIBCO BRL) for 1 wk, incubated without aminopterin in DME containing 1 • hypoxanthine-thymidine medium (GIBCO BILL) for 4 d, and passaged routinely in complete DME (36) . IFN-oe responsiveness was confirmed by demonstrating MHC class I induction.
Northern Blot Hybridizations. Northern blots were performed as described previously (19) . A CIlTA cDNA fragment was generated by PCR from a Daudi cell cDNA library kindly provided by Dr. Taolin Yi (Cleveland Clinic Foundation) using primers that amplified residues 2909-3534 of the published sequence (42) . The identity of the amplified segment was confirmed by sequence analysis, after which a gel-isolated fragment was labeled by random priming for hybridization.
Normalized Transient Transfections. Cells were cultured in 10-cm 2 dishes to "~70-80% confluence in the presence or absence of IFN-[3. Medium was replaced with 3 rnl ofprewarmed complete medium containing 10-20 ~g ofpDRA(267)CAT plasmid DNA, 2-4 Ixg of pGL2 luciferase expression plasmid DNA (Promega Corp.), and 10 Ixg/ml Polybrene for 6 h, and the cells were washed once with PBS and shocked with 30% DMSO in 3 rnl of serum-free media for 2 rain at room temperature. Cells were washed twice with incomplete medium and incubated for 48 h in complete medium before harvesting and normalized CAT assay. Cells were scraped in 1.4 ml PBS, pelleted for 2 rain in a microcentrifuge, and resuspended in 70 I.tl of 1• luciferase lysis buffer (Promega Corp.). Cell extracts were prepared by lysis with three cycles of freezing and thawing and clarified for 10 rain in a microcentrifuge. 10 btl of extract was subjected to luciferase assay according to the manufacturer's instructions. Extract input to CAT assays was normalized to luciferase activity to correct for transfection efficiency.
Flow Cytometry, Cells were immunostained for HLA-DIL and an isotype-matched control and analyzed on a FACscan | (Becton Dickinson & Co., Mountain View, CA) as described (12) . For each data point, the percentage of cells staining with isotypematched control was subtracted from the experimental value, and results were expressed as the percentage of HLA-DR-positive cells.
Because of variability in HLA-DIL induction, data for these experiments were not normally distributed; however, the percentages of inhibition by 1FN-o~ and IFN-~ were highly reproducible. Representative experiments are presented in the figures. Mean inhibitions of HLA-DIL induction in preliminary experiments were as follows: by IFN-oL in 2f'TGH cells, 71.3% (n = 2); by IFN-13 in 2fTGH cells, 94.2% (n = 6); by IFN-ot in U1A cells, 20% (n = 2); by IFN-[3 in UIA cells, 48.8% (n = 2); by IFN-0~ in U2A cells, 0% (n = 1); by IFN-13 in U2A cells, 5% (n = 3).
Results

IFN-'y-induced CIITA mRNA Accumulation Is Not Affected by IFN-~8.
It has recently been shown that CIITA was necessary for IFN-'y-induced MHC class II transcription (30, 31, 33) . This surprising result provided a unitary explanation for distinctive characteristics of IFN-'y regulation of MHC class II expression, including the requirement for ongoing protein synthesis.
We considered the possibility that IFN-[3 might inhibit synthesis of CIITA as a plausible mechanism for suppressing MHC class II expression. Northern blot hybridizations showed that CIITA mtLNA was induced in 2fTGH fibrosarcoma cells by IFN-3,. C I I T A m k N A accumulation was unaffected by I F N -~ treatment at saturating concentrations that, in preliminary experiments, completely abrogated M H C class II expression (Fig. 1) . This result indicated that the inhibition of M H C class II expression by I F N -~ was not mediated by blocking C I I T A m I~N A accumulation. 
IFN-~ Blocks Expression of MHC
ISGF3-T Is Required for IFN-~-mediated Inhibition of IFN-T-induced MHC Class II Expression. IFN-[3 treatment
activates a signaling cascade that culminates in expression of gene products, which in turn mediate many of the biological effects attributed to IFN-[3. One possible mechanism by which IFN-[3 could inhibit MHC class II transcriptional induction was by activation of a preexisting signaling component (e.g., protein kinase) in the IFN-[3 pathway. Alternatively, IFN-[3 could require de novo gene expression to impair transcriptional induction of MHC class II genes.
It was possible to test the role of IFN-13-activated signaling components in the inhibition of MHC class II through the use of cell line U2A, which lacked functional ISGF3-~ (1, 38) . Despite the absence of functional ISGF3-~/in U2A cells, IFN-a/~ signaling leading to the generation of activated STAT-la/STAT-2 heterodimers (ISGF3-a) has been documented (1, 38) . Furthermore, studies in U2A cells showed that IFN-ot induces expression of the IRF-1 gene through an alternative pathway that generates DNA-binding complexes containing STAT-la (39) . These results documented that U2A cells have intact IFN-a/[3-activated signaling components, which include the IFN-a/13 receptor complex, JAK1, tyk2, STAT-lcx, and STAT-2 (39). U2A was shown in these studies to be deficient only in ISREregulated gene expression.
IFN-13 failed to inhibit IFN-'y-induced MHC class II antigen expression in mutant U2A cell line (Fig. 3) . This result suggests that ISGF3-~/ is required for down-regulation of IFN-~/-induced MHC class II expression; however, one possible trivial explanation for this observation would be a second site mutation in U2A cells. To address this issue, we restored functional ISGF3-~/ by transfection and back-selection, producing cell line U2A/p48, which was fully responsive to IFN-~. In U2A/p48 cells, IFN-[3 suppressed MHC class II induction equally as observed in the wildtype 2fTGH line, demonstrating formally that ISGF3-~/ was required for IFN-13 to inhibit MHC class II expression (Fig. 4) . These observations suggest that IFN-[3 acts through the ISGF3/ISRE-dependent pathway to induce the expression of gene(s) whose product(s) mediate the inhibition of MHC class II transcriptional induction.
To address further the role of gene expression in IFN-[3 inhibition of MHC class II, we performed studies in mutant cell line U1A, which was deleted for PTK tyk2, defective in IFN-a binding to the receptor, and completely un- 
ISGF3-'y Is Required for IFN-[3-mediated Inhibition of CIITA-induced MHC Class II Transcription.
Our results suggest that IFN-[3 inhibits IFN-',/-induced M H C class II expression by impairing transcriptional induction from M H C class II promoters, even in the presence of C I I T A (Fig. 2) . U 2 A cells were used to study the role of IFN-t3-activated signaling components in inhibiting M H C class II induction (20) . 2fTGH/CIITA.2.11 cells or U2A/CIITA.2.11 cells were exposed to IFN-[3 (500 U/ml) overnight or left as untreated controls before washing and transient cotransfection with pDR.A(267)CAT (10 ~g) and pGL2 (5 Izg). Cells were then incubated in complete medium with or without IFNs as indicated for 48 h before harvest. An aliquot of the cell lysate was subjected to luciferase assay, and luciferase activity was used to correct extract inputs to CAT assays to normalize for transfection efficiency. An autoradiogram is shown; the percentage of conversion of CAT to acetylated product (% CAT) was determined by autoradiography on a Phosphorlmager. The percentage of inhibition of promoter activity by IFN-[3 (% INH) was determined as described in the legend to Fig. 4 and is indicated below. (Figs. 3 and 4) . To address the role of these signaling components in suppressing CIITA-driven M H C class II expression, U2A cells that stably expressed CIITA.2.11 were constructed. Strikingly, IFN-[3 failed to inhibit expression o f pDRA(267)CAT in U2A/CIITA.2.11 cells in normalized transient transfections (Fig. 5) . This observation further supports the conclusion that IFN- [ (43, 44) . Our data localize the inhibitory effect of I F N -~ for M H C class II expression subsequent to I F N -yinduced CIITA mP, N A accumulation.
We observed that IFN-[3 treatment significantly impaired expression of M H C class II promoters in CIITA-expressing cells in transient transfection experiments (Fig. 2) . This result indicates that CIITA protein is not fully functional in IFN-[3-treated cells. The most straightforward explanation for this effect of IFN-[3 treatment would be that accumulation or competence of C I I T A protein is modulated. Potential mechanisms include destabilization or posttranslational modification of the C I I T A protein, abrogation of CIITA interaction with M H C class II-specific factors associated with promoter elements, or blockade of nuclear accumulation of CIITA. A plausible alternative is that IFN-[3 treatment could result in modification or displacement of any of the components required for M H C class II transcription, including the factors (such as P,F-X, X2BP, NF-Y) that contact D N A directly. The interference with these factors would then secondarily produce an apparent abrogation of CIITA function.
In other systems, IFN-mediated transcriptional inhibition has shown varied characteristics. Vilcek and colleagues showed that the IFN-mediated inhibition of TNF-ixinduced IL-8 did not require protein synthesis, and the ef-fect was shortlived (45) . We used mutant cell lines for IFN signaling components to address whether gene expression was required for the inhibition of IFN-~/-induced and CIITA-driven MHC class II transcription. The most informative mutant was U2A, a cell line lacking ISGF3-~/but otherwise competent for IFN signaling. IFN-~-mediated inhibition was not observed for the endogenous MHC class II genes that were constitutively expressed in CIITA-transfected cells. Furthermore, when IFN-[5 treatment was introduced 12 h after transfection with MHC class II promoter-driven constructs, no inhibition was observed (data not shown). These characteristics were similar to those we reported previously for IFN-[3 effects on expression of the MHC class II genes. In particular, IFN-13 failed to inhibit constitutive MHC class II expression by human monocytes (19, 49) . Further, we previously observed that IFN-[3 did not block MHC class II induction in human astrocytoma cells that were highly sensitive to such inhibition, when added ~>6 h after IFN-~/(Ransohoff, R., and G.T. Babcock, unpublished observations). These observations may indicate that CIITA is not susceptible to the inhibitory effects of IFN-13 after its production and activation. In this context, it is not certain whether CIITA expression by DNA-mediated gene transfer is identical in all respects to its induction by IFN-% and in particular whether posttranslational modifications occur in IFN-~/-induced cells. The stoichiometric relationship between CIITA and IFN-[3-induced inhibitor(s) may also be critical for interpretation of these experiments. It is possible that CIITA levels in stably transfected cells are sufficient to titrate IFN-[5-induced components, so that inhibition of MHC class II promoter expression is relatively modest (Fig. 2) .
Recent information about functional domains of CIITA has come from detailed structure-function analysis (34, 35) . A surprisingly strong NH2-terminal acidic transactivation domain functions efficiently for heterologous promoters and in yeast cells, indicating general competence as a eukaryotic transactivator. CIITA requires the conserved MHC class II DNA elements to drive transcription, a property that is conferred by the COOH terminus of the protein, possibly through physical interaction with factors that contact DNA directly. Our finding that CIITA function is sensitive to IFN-[3 action suggests the prospect that CIITA-mediated transactivation or interaction with DNA-binding factors may be targeted by an IFN-inducible component. These possibilities can be experimentally addressed.
